EyePoint Pharmaceuticals Raises $150 Million to Advance DURAVYU Phase 3 Trials for Retinal Diseases
核心洞察
EyePoint Pharmaceuticals announced a $150 million public offering to fund clinical development of DURAVYU for wet age-related macular degeneration (搜索) and diabetic macular edema (搜索).
DURAVYU combines vorolanib, a selective tyrosine kinase inhibitor, with the company's bioerodible Durasert E technology for sustained delivery treatment.
The investigational therapy is currently in Phase 3 pivotal trials for wet AMD with data expected in mid-2026, while Phase 3 trials for diabetic macular edema (搜索) are planned to begin in Q1 2026.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced on October 14, 2025, that it has commenced an underwritten public offering of $150 million of shares of its common stock to advance clinical development of its lead product candidate DURAVYU for serious retinal diseases. The company has also granted underwriters a 30-day option to purchase up to an additional $22.5 million of shares at the public offering price.
The Watertown, Massachusetts-based clinical-stage biopharmaceutical company intends to use the net proceeds to advance clinical development of DURAVYU for wet age-related macular degeneration (搜索) (wet AMD) and diabetic macular edema (搜索) (DME), support its earlier-stage pipeline development initiatives, and for general corporate purposes.
DURAVYU Technology and Clinical Development
DURAVYU is an innovative investigational sustained delivery treatment for VEGF (搜索)-mediated retinal diseases that combines vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), in next-generation bioerodible Durasert E technology. The therapy is supported by robust safety and efficacy data to date, according to the company.
The investigational treatment is currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (搜索), with data anticipated in mid-2026. First patient dosing in the pivotal Phase 3 clinical trials for diabetic macular edema (搜索) is expected in the first quarter of 2026.
Company Background and Partnerships
EyePoint has established itself in the retinal disease space with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation. The company operates from its headquarters in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences (搜索), a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan. DURAVYU has been conditionally accepted by the FDA as the proprietary name for EYP-1901, though the company notes that DURAVYU is an investigational product that has not been approved by the FDA.
Offering Details
J.P. Morgan, Jefferies, Citigroup, and Guggenheim Securities are acting as joint book running managers for the offering. The offering is subject to market conditions, and the company notes there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The securities are being offered pursuant to an automatically effective shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission. The securities will be offered by means of a prospectus supplement and accompanying prospectus relating to the offering that form part of the registration statement.